Nasus Pharma CFO Eyal Rubin to resign, interim successor named

Nasus Pharma Ltd. (NYSE American: NSRX) announced on August 19, 2026 that Chief Financial Officer Eyal Rubin will be leaving the Company to pursue a new opportunity outside of the life science industry.¹

Rubin will remain with Nasus through September 18, 2026, and will work closely with the Company to ensure a seamless and orderly transition.¹ According to the company's 6-K filing, the resignation will become effective on September 18, 2026, and was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.¹

Oren Elmaliach, the Company's Director of Finance, has been appointed Interim Chief Financial Officer.¹ The filing states Elmaliach will serve as interim Chief Financial Officer until the appointment of a successor.¹

The company said Elmaliach has been with Nasus since its inception and has extensive knowledge of the Company's financial operations, reporting processes and organization, and is a certified public accountant with more than 15 years of financial experience and leadership including significant experience supporting public and private life sciences companies and working within the US public markets and financial reporting environment.¹

CEO Brendan O'Grady and Chairman Udi Gilboa both commented on the transition, with Gilboa stating Rubin made meaningful contributions to Nasus, playing an important role in our transition as a public company and in building the financial foundation for our next stage of development.¹

Nasus describes itself as a biopharmaceutical company advancing innovative intranasal therapies through its proprietary intranasal powder technology platform¹, with lead candidate NS002 being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis.¹